tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
PremiumRatingsAnalyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
3M ago
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
3M ago
Cognition Therapeutics conducts zervimesine meeting with FDA
Premium
The Fly
Cognition Therapeutics conducts zervimesine meeting with FDA
3M ago
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
PremiumThe FlyCognition Therapeutics’ zervimesine shows eficacy in dementia trial
5M ago
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
Premium
Ratings
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
5M ago
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
5M ago
Cognition publishes Phase 2 results on Zervimesine
PremiumThe FlyCognition publishes Phase 2 results on Zervimesine
7M ago
Cognition Therapeutics Launches New $75M ATM Offering
Premium
Company Announcements
Cognition Therapeutics Launches New $75M ATM Offering
8M ago
Cognition Therapeutics files $300M mixed securities shelf
Premium
The Fly
Cognition Therapeutics files $300M mixed securities shelf
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100